Navigation Links
GenVec Achieves Second Milestone in Collaboration
Date:12/6/2011

nd balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the collaboration with Novartis, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (S
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 LayerBio, Inc., an MIT ... its first round of seed financing from friends and ... efforts to develop a novel sustained-release product for ophthalmology. ... investors and their commitment to this important work," said ... is one of many areas in which innovations in ...
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report Strategic ... report provides in-depth analysis of the current trends ... capital segments of the financial industry, bearing in ... impact on the future of emerging biotechnology companies ... identifies regions of the world that are attracting ...
(Date:7/29/2014)... 29, 2014 The advanced optical methods ... that are driving a revolution in the neurosciences were ... journal published by SPIE, the international society for ... with the launch of the BRAIN Initiative in the ... lay out a vision for and provide examples of ...
(Date:7/29/2014)... , July 29, 2014 Human Longevity, Inc. ... company focused on extending the healthy, high performance human ... Och , Ph.D., an expert in machine learning and ... comes to HLI from Google where he was Distinguished ... will report directly to HLI Co-Founder and CEO, ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... today announced,the appointment of Tim Ravenscroft as chief ... "The board of Lentigen,is delighted that Tim has ... to enter,clinical trials for our first therapies later ... background and global leadership in,healthcare products will serve ...
... EXTON, Pa., Jan. 28 BioTrends Research Group, ... report offering comprehensive insight into the management of,renal ... Kidney Disease,(CKD). The report is based on responses ... in the US, during December 2007., In ...
... Provides a Neuroprotective Effect in Preclinical Model of ... ... /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a biotechnology company ... target the destructive,inflammatory process associated with the development and progression ...
Cached Biology Technology:Lentigen Appoints Tim Ravenscroft as Chief Executive Officer 2BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2Vasogen's Research Published in European Journal of Neuroscience 2Vasogen's Research Published in European Journal of Neuroscience 3Vasogen's Research Published in European Journal of Neuroscience 4Vasogen's Research Published in European Journal of Neuroscience 5
(Date:7/29/2014)... Territories in Canada and have sent smoke drifting down ... NASA,s Aqua satellite collected this natural-color image with ... 26, 2014. Actively burning areas, detected by MODIS,s thermal ... are drifting northward in this image. Smoke is ... has caused power outages in the area and because ...
(Date:7/29/2014)... University of Kent has shown for the first time ... breakthrough that could have a major impact on cancer ... Biosciences uncovered the mechanism whereby the physical properties of ... filaments are ,fine-tuned, to undertake different functions. , ... stable, providing a framework for the cell, others are ...
(Date:7/29/2014)... A ground breaking new book that brings together two ... to raise the profile of insect fossils through stunning ... David Penney and James E Jepson, details the incredible ... world, setting the scene for what these remarkable fossils ... and even the future of our planet. Like the ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2
... 25, 2013) -- Twenty grams of essential amino acids taken twice ... surgeries helped 16 patients, mean age 69, recover faster and with ... The approach -- detailed in a paper now online ahead ... of Clinical Investigation -- could spell relief and speed recovery ...
... of Medicine (BUSM) have discovered a molecule that could help ... as its treatment. Using RNA sequencing, the team looked at ... less abundant in people with lung cancer and inhibits lung ... Proceedings of the National Academy of Sciences , suggest ...
... millions of years ago are recorded at daily rate ... huge X-ray microscope has revealed growth bands in plankton ... temperature. The results could allow scientists to chart ... of years ago. Plankton shells show features like ...
Cached Biology News:Oregon researchers say supplement cuts muscle loss in knee replacements 2Oregon researchers say supplement cuts muscle loss in knee replacements 3Oregon researchers say supplement cuts muscle loss in knee replacements 4BUSM researchers identify molecule that could aid lung cancer detection, treatment 2Reading ancient climate from plankton shells 2
...
... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
...
...
Biology Products: